We then developed FcRH5 CAR-T cells and demonstrated that FcRH5 CAR-T cells mediated equivalent anti-tumor efficacy against MM cells or other target cells co-expressing FcRH5 and BCMA in comparison to BCMA CAR-T cells both in vitro and in two widely used MM xenograft murine models. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.